AstraZeneca has entered into a definitive agreement to acquire EsoBiotec, a biotechnology company pioneering in vivo cell therapies that has...
Vous n'êtes pas connecté
AstraZeneca has entered into a definitive agreement to acquire EsoBiotec, a biotechnology company pioneering in vivo cell therapies that has demonstrated promising early clinical activity. The EsoBiotec Engineered NanoBody Lentiviral (ENaBL) platform empowers the immune system to attack cancers and could offer many more patients access to ...
AstraZeneca has entered into a definitive agreement to acquire EsoBiotec, a biotechnology company pioneering in vivo cell therapies that has...
Alumis Inc, a clinical─stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and...
Vertex has announced that its Phase 1/2 trial for its VX-880 stem cell-derived islet therapy is converting to a Phase 1/2/3 pivotal trial, enrolling...
Chimeric antigen receptor T-cell (CAR-T) therapy has emerged as a transformative force in cancer treatment, particularly within the realm of cell...
IPFone, a leader in Unified Communications and Internet services, today announced the signing of a definitive agreement to acquire TelNet Worldwide,...
IPFone, a leader in Unified Communications and Internet services, today announced the signing of a definitive agreement to acquire TelNet Worldwide,...
KUALA LUMPUR: NCT Alliance Bhd’s unit NCT Panorama Sdn Bhd has entered into a conditional sale of shares agreement with Herman Lee and Melvin Lee to...
Riverbank Solutions Limited, founded by Nick Mwendwa, the former president of the Football Kenya Federation (FKF), specializes in developing and...
Riverbank Solutions Limited, founded by Nick Mwendwa, the former president of the Football Kenya Federation (FKF), specializes in developing and...
Antibody treatment which activates the patient’s immune system against cancer, known as immunotherapy, is increasingly being investigated as an...